A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Sponsor
The People's Hospital of Leshan
Study ID
NCT03393507
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
  • Taxus + platinum — DRUG
    Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.

Study Details

The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer

Key Dates

Start date
Aug 1, 2017
Status verified
Jan 2018
Primary completion
Dec 1, 2018
Completion
Dec 1, 2019

Study Design

Enrollment
34 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib combine with chemotherapy
  • Active Comparator: chemotherapy

Primary Outcome Measure

PFS(Progress free survival) [ Time Frame: 24 month ]

Central Contacts

Related Studies